Open an account

Inmode

INMD · NASDAQ

$13.97−$0.08 (−0.57%)TodayMarket closed ·
Prev close $14.05

About INMD

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. The company is headquartered in Yokneam, Northern (Hazafon) and currently employs 660 full-time employees. The company went IPO on 2019-08-08. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The firm have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.

Employees
660
Headquarters
Yokneam, Northern (HaZafon)
Listed
Aug 8, 2019
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
inmodemd.com

INMD key statistics

Market cap
803.89M
Price-earnings ratio
11.52
Dividend yield
—
Average volume
461.76K
Volume
420.75K
Open price
$14.00
High today
$14.05
Low today
$13.93
52 Week high
$16.67
52 Week low
$12.72

Inmode (INMD) at a glance

As of Oct 23, 2026, Inmode (INMD) shares are priced at $13.97, giving the company a market cap of 803.89M and a price-to-earnings ratio of 11.52.

Today the stock has traded between $13.93 and $14.05. The current price is 0.3% above the day's low and 0.6% below its high.

Volume so far is 420.75K shares, in line with the average of 461.76K shares a day.

Over the past year Inmode has ranged from $12.72 to $16.67, and now sits 32% of the way up that range.

Inmode met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.35 per share against an estimate of $0.3393.

The average analyst price target is $16.49, 18.0% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

25%of 4 analyst ratings say Buy
  • Buy25.0%
  • Hold75.0%
  • Sell0.0%
Price target · 5 analystsAvg $16.49
Low
$15.15
Now
$13.97
High
$17.85

INMD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 7.2% on average.

  1. Q3 FY24: reported $0.70 per share against an estimate of $0.6429
  2. Q4 FY24: reported $0.42 per share against an estimate of $0.5268
  3. Q1 FY25: reported $0.31 per share against an estimate of $0.3592
  4. Q2 FY25: reported $0.47 per share against an estimate of $0.4249
  5. Q3 FY25: reported $0.38 per share against an estimate of $0.3615
  6. Q4 FY25: reported $0.46 per share against an estimate of $0.4258
  7. Q1 FY26: reported $0.25 per share against an estimate of $0.3028
  8. Q2 FY26: reported $0.35 per share against an estimate of $0.3393

INMD news

  • Press releaseBusiness Wire

    Steel Partners Holdings L.P. Issues Open Letter to All InMode Stakeholders and Sets October 30, 2026 Expiration for Its $16.75 Per Share All-Cash Offer

  • Press releasePRNewswire

    InMode to Report Third Quarter 2026 Financial Results on November 11, 2026, Expects Third Quarter Revenue of $91.8 Million to $92.0 Million, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

  • Press releasePRNewswire

    InMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool

  • Press releasePRNewswire

    A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture

  • Press releasePRNewswire

    InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025

  • Press releaseGlobe Newswire

    Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One

  • Press releaseBusiness Wire

    Steel Partners Urges InMode Shareholders to Vote AGAINST the Re-Election of Dr. Hadar Ron and AGAINST Extraordinary Special Committee Compensation at the July 30 Annual General Meeting

  • Press releaseBusiness Wire

    Steel Partners Holdings L.P. Issues Letter to InMode Ltd. Board of Directors Regarding the Company’s Persistent and Egregious Governance Failures

Similar companies

Companies in the same industry as Inmode

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.